If Eli Lilly presents strong data, the stock could be set to rally and potentially be on a path to reaching new highs. Should ...

Weight loss drugs like Ozempic and Wegovy are used by over 15 million adults in the U.S., or 4.5% of the population. Despite ...

The New Science of Achieving a Healthy Weight” (Flatiron Books), former FDA Commissioner David A. Kessler argues that ultraprocessed foods — meaning ...

Excessive weight has been a persistent problem in America, where at least one in five adults in each U.S. state is living ...

Health-care companies rose amid sales growth optimism. Drug-store chain CVS Health said it has seen complaints of strong push back from patients on its pharmacy-benefit manager's move to favor Novo ...

GLP-1 weight loss drugs, such as Wegovy and Zepbound, have helped millions of people shed weight and curb food cravings. But they create additional health problems, Kessler says, and there's not ...

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, ...

Scientists know the stomach talks to the brain, but two new studies from Rutgers Health researchers suggest the conversation ...

Researchers found that injectable GLP-1 receptor agonists for obesity tended to yield smaller reductions in weight in ...

A Cleveland Clinic study shows that semaglutide and tirzepatide – injectable GLP-1 drugs for obesity – produce smaller weight ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...